Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 261 results for carcinoma

  1. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153

  2. Lung cancer in adults (QS17)

    This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    13 December 2019
    View quality statements

    Sections for QS17

  3. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

    Medtech innovation briefing
    Published
    18 January 2018

  4. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA443

  5. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA242

  6. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

    Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.

    Technology appraisal guidance
    Published
    31 January 2018
    View recommendations

    Sections for TA501

  7. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA430

  8. Paige Prostate for prostate cancer (MIB280)

    NICE has developed a medtech innovation briefing (MIB) on Paige Prostate for prostate cancer .

    Medtech innovation briefing
    Published
    30 November 2021

  9. ATEC system for vacuum-assisted breast biopsy (MIB43)

    NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system

    Medtech innovation briefing
    Published
    10 November 2015

  10. ADXBLADDER for detecting bladder cancer (MIB180)

    NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .

    Medtech innovation briefing
    Published
    12 April 2019

  11. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)

    Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

    Technology appraisal guidance
    Published
    16 March 2022
    View recommendations

    Sections for TA779

  12. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

    Technology appraisal guidance
    Published
    24 October 2012
    View recommendations

    Sections for TA265

  13. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

    Technology appraisal guidance
    In development

  14. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    Discontinued Reference number: GID-TA11005

    Technology appraisal guidance
    Discontinued

  15. Laparoscopic partial nephrectomy (IPG151)

    Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.

    Interventional procedures guidance
    Published
    25 January 2006
    View recommendations

    Sections for IPG151